Bat virome

UVDI-360 Room Sanitizer Inactivates SARS-CoV-2 at 12 Feet (3.65 Meters) Distance in 5 Minutes

Retrieved on: 
Thursday, January 14, 2021
Medical Supplies, Health, Infectious diseases, Hospitals, Other Health, Managed care, General Health, Sarbecovirus, Animal diseases, Zoonoses, Respiratory diseases, Bat virome, Animal virology, Severe acute respiratory syndrome, Coronavirus disease, Coronavirus

UltraViolet Devices, Inc. (UVDI) announced its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10, inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters).

Key Points: 
  • UltraViolet Devices, Inc. (UVDI) announced its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10, inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters).
  • View the full release here: https://www.businesswire.com/news/home/20210114005585/en/
    The UVDI-360 Room Sanitizer is used in approximately 1,000 hospitals globally.
  • (Photo: Business Wire)
    The testing parameters were carefully selected to be indicative of rapid whole room disinfection in hospitals.
  • We hope this important testing can lend confidence and comfort to Healthcare professionals working bravely and tirelessly to beat COVID-19.

EUROIMMUN Launches SARS-CoV-2 Test System to Detect T-Cell Response

Retrieved on: 
Thursday, January 14, 2021
Biotechnology, Medical devices, Infectious diseases, Health, Pharmaceutical, Sarbecovirus, Zoonoses, Medicine, Medical specialties, Animal diseases, Bat virome, Severe acute respiratory syndrome, Immune system, ELISA, COVID-19 testing, Coronavirus disease

Evidence suggests that both pillars of the immune system, antibody and T-cell response, are important in understanding immunity against SARS-CoV-2 reinfections.

Key Points: 
  • Evidence suggests that both pillars of the immune system, antibody and T-cell response, are important in understanding immunity against SARS-CoV-2 reinfections.
  • The detection system is based on the well-established ELISA technology and can be processed manually or automatically in most laboratory settings.
  • For this reason, the assay can be a helpful tool in research studies evaluating the cellular immune response in SARS-CoV-2 infected or vaccinated individuals.
  • We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise.

Independent Test Results confirm an inhibitory effect on the novel coronavirus (SARS-CoV-2) by Panasonic’s air conditioner with nanoe™ X

Retrieved on: 
Thursday, January 14, 2021
Consumer electronics, Health, Technology, Infectious diseases, Research, Science, Bat virome, Companies, Technology, Manufacturing, Coronaviridae, Zoonoses, Air conditioning, Ancient Roman technology, Conditioner, Novel coronavirus, Severe acute respiratory syndrome, Panasonic

In September 2020, and in collaboration with Texcell*1, Panasonic verified the inhibitory effect of the nanoe X technology with the benefits of hydroxyl radicals on the novel coronavirus in a small test space of 45L using nanoe X generator.

Key Points: 
  • In September 2020, and in collaboration with Texcell*1, Panasonic verified the inhibitory effect of the nanoe X technology with the benefits of hydroxyl radicals on the novel coronavirus in a small test space of 45L using nanoe X generator.
  • For further investigation, Panasonic challenged to test using an air conditioner with nanoe X in a larger test space.
  • Even in these difficult circumstances, Texcell has now certified that the nanoe X does have a 91.4% inhibitory effect on the novel coronavirus in the actual space of 6.7m3 over 8 hours using the air conditioner with nanoe X.
  • Testing the inhibitory effect of air conditioner with nanoe X on the novel coronavirus (SARS-CoV-2) in a space of 6.7m3.

New England Biolabs Expands its Luna® Portfolio with the SARS-CoV-2 RT-qPCR Multiplex Assay Kit

Retrieved on: 
Tuesday, January 12, 2021
Natural sciences, Laboratory techniques, Science and technology, Molecular biology, Branches of biology, New England Biolabs, Biotechnology, Bat virome, Real-time polymerase chain reaction, Polymerase chain reaction, NEB, Severe acute respiratory syndrome

IPSWICH, Mass., Jan. 12, 2021 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of its LunaSARS-CoV-2 RT-qPCR Multiplex Assay Kit for real-time detection of SARS-CoV-2 nucleic acid.

Key Points: 
  • IPSWICH, Mass., Jan. 12, 2021 /PRNewswire/ --New England Biolabs (NEB) today announced the launch of its LunaSARS-CoV-2 RT-qPCR Multiplex Assay Kit for real-time detection of SARS-CoV-2 nucleic acid.
  • "To address this, we specifically developed the Luna SARS-CoV-2 RT-qPCR Multiplex Assay Kit by modifying the Centers for Disease Control and Prevention (CDC)-designed RNase P control reverse primer to avoid spurious amplification of human genomic DNA.
  • "With these enhancements, the kit achieves strong multiplex detection with 24 hours of room temperature stability.
  • Luna, NEB, and NEW ENGLAND BIOLABS are registered trademarks of New England Biolabs, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/new-england-biolabs-expands-its-...

Valeo Pharma Highlights MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19

Retrieved on: 
Tuesday, January 12, 2021
Zoonoses, Sarbecovirus, Branches of biology, Organic compounds, Health, Orthomolecular medicine, Nutrition, Bat virome, Coronavirus disease, Vitamin C, Severe acute respiratory syndrome, Vitamin

(CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, provided comments today on a recently issued newsletter by MDBriefCase entitled "Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C".

Key Points: 
  • (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, provided comments today on a recently issued newsletter by MDBriefCase entitled "Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C".
  • The complete newsletter is available at: Read+more+about+the+need+for+novel+approaches+to+SARS-CoV-2_v2.pdf[93].pdf (valeo-hesperco.s3.ca-central-1.amazonaws.com)
    According to the newsletter, Hesperidin has recently attracted the attention of researchers, because it binds to key proteins of SARS-CoV-21.
  • In discussing vitamin C, the newsletter noted that vitamin C did not demonstrate affinity to receptors that would interfere with SARS-CoV-2 infectivity2.
  • A complementary therapeutic effect of intravenous high doses of vitamin C has been reported and clinical trials are ongoing1.

New FDA Cleared Air Purifier Eliminates COVID-19 Virus in 15 Minutes

Retrieved on: 
Monday, January 11, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, Occupational safety and health, Bat virome, Coronavirus disease, Severe acute respiratory syndrome

Brondell has the exclusive rights to sell and market its own air purifier using AG+ Technology in North America.

Key Points: 
  • Brondell has the exclusive rights to sell and market its own air purifier using AG+ Technology in North America.
  • "COVID-19 is spread through aerosol droplet transmission that travels and lingers in the air.
  • Both tests concluded the Brondell Pro with AG+ Technology effectively eliminates the SARS CoV-2 virus.
  • "The aerosolized test resulted in no detectable levels of SARS-CoV-2 after 15 minutes with the air purifier in operation," said Dr. Solocinski, Staff scientist at MRIGlobal.

DGAP-News: CureVac : CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

Retrieved on: 
Monday, January 11, 2021
Zoonoses, Sarbecovirus, Medicine, Medical specialties, Animal diseases, Bat virome, Vaccination, COVID-19 vaccine, Medical research, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, Coronavirus disease

CureVac : CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

Key Points: 
  • CureVac : CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
    The issuer is solely responsible for the content of this announcement.
  • Furthermore, rhesus macaques were shown to be protected from challenge infection with SARS-CoV-2 following vaccination with 8g of CVnCoV.
  • "Full protection of the lungs of vaccinated animals supports CVnCoV's potential in protecting humans from the devastating effects the virus has.
  • The quality of immune response was comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.

FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health Care Providers and Clinical Laboratory Staff

Retrieved on: 
Friday, January 8, 2021
Medicine, Sarbecovirus, Clinical medicine, Infectious diseases, Bat virome, Severe acute respiratory syndrome, Medical laboratory, Food and Drug Administration, COVID-19 testing, Coronavirus disease

"The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients," said FDA Commissioner Stephen M. Hahn, M.D.

Key Points: 
  • "The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients," said FDA Commissioner Stephen M. Hahn, M.D.
  • The FDA will continue to keep health care providers and the public informed of any new information as it becomes available."
  • The FDA has reminded clinical laboratory staff and health care providers about the risk of false negative results with all laboratory tests, including molecular tests.
  • Laboratories should expect some false results to occur even when very accurate SARS-CoV-2 tests are used.Today's announcement also provides important information and recommendations for clinical laboratory staff and health care providers who use molecular tests for the detection of SARS-CoV-2.

Labcorp Awarded CDC Contract to Study Variants of COVID-19 Virus and Improve Public Health Response

Retrieved on: 
Thursday, January 7, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Genetics, Branches of biology, Biology, Life sciences, Sarbecovirus, Bat virome, Genomics, Burlington, North Carolina, LabCorp, Severe acute respiratory syndrome coronavirus, Whole genome sequencing, Severe acute respiratory syndrome, COVID-19 testing

The survey aims to provide important baseline information for national and state-level surveillance, help define changes in transmission, identify new variants of the virus, and improve the public health response to the virus.

Key Points: 
  • The survey aims to provide important baseline information for national and state-level surveillance, help define changes in transmission, identify new variants of the virus, and improve the public health response to the virus.
  • Through this program, the CDC aims to more than double the rate of genomic samples sequenced per week.
  • Labcorp will sequence the genomes of random de-identified samples that test positive for SARS-CoV-2 and will provide the CDC with completed sequences.
  • Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives.

Clear Labs Partners with IDT to Automate and Improve Accuracy of COVID-19 Testing

Retrieved on: 
Thursday, January 7, 2021
Bat virome, Respiratory diseases, Sarbecovirus, Severe acute respiratory syndrome, Animal diseases, Medicine, COVID-19 testing

Clear Labs' EUA approved, turnkey sequencing platform for diagnostic screening and genomic surveillance of SARS-CoV-2 utilizes IDT primers as part of its solution.

Key Points: 
  • Clear Labs' EUA approved, turnkey sequencing platform for diagnostic screening and genomic surveillance of SARS-CoV-2 utilizes IDT primers as part of its solution.
  • The Clear Labs EUA-approved, turnkey sequencing platform for diagnostic screening and genomic surveillance of SARS-CoV-2, is available now.
  • Clear Labs' turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2.
  • With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow's novel pathogens.